Amgen’s mission is clear cut: ‘To Serve Patients’, which is evident in the level of innovation that they bring as the world’s leading biotech company. Complementary to this message is one that GM of Amgen Greece Arvela Matti, strongly wants to reverberate across the Greek pharmaceutical landscape: innovation is an investment. In charge of spearheading the affiliate through the economic crisis, he speaks about his affinity for challenges, his ideal model of collaboration for this environment, as well as the importance of staying resilient. Your first Country Director position was in Finland, which you held for four years, before coming to Greece during one of the toughest years of the economic crisis. What prompted this change in career path?
"As an innovative company with a substantial area of expertise in biotechnology, as well as a strong commitment to R&D, Amgen has always been a proponent of a system wherein value is acknowledged and differentiated."